Resumen

VASQUEZ RIOS, Juan Carlos. PREGABALINA LIKE THERAPEUTIC OPTION IN PERIPHERAL NEUROPATHIC PAIN AND OTHER NEURALGIA TREATMENT. Rev. Méd.-Cient. Luz Vida [online]. 2010, vol.1, n.1, pp. 26-30. ISSN 2219-8032.

Pregabalina is a new drug of neuromodulador group with a better pharmacokinetics profile than its prede-cessors with indication in peripheral neuropathic pain. Its appearance opens new horizons in treatment of patients with this complaint. Pregabalina is a GABA analogous, although it does not bind to its receptor and is not able to develop characteristic actions. Analgesic effect is possible to its better capacity to bind to alpha-2-deltha protein subunit of the voltage-dependent calcium channels in Central Nervous System (CNS) than Gabapentine. In several pain animals' models, Pregabalina has demonstrated effectiveness antihyperalgesic and antialodi-nic profile better than morphine and amitriptyline; it is absorbed quickly by digestive tract with 90% of bioa-vailability, highly predictable and linear pharmacokinetics with long half-life, which allows its administration in two daily doses. Pregabalina does not bind to plasma proteins and it has intact elimination almost totality, that is why it presents tiny interaction with other drugs. In all pain animals' models, 150 mg of Pregabalina at day or superior has demonstrated to be more effectiveness than placebo, just with a dose-dependent form to control pain, to improve sleep and life's quality of patients. 600 mg is the most effective dose demonstrated with 457 mg/day as half-dose. It also showed high effectiveness. Pregabalina in therapeutic doses has demonstrated high indices of security with low incidence, slight and reversible adverse effects. Similar serious adverse effects were also founded with placebo. In conclusion, it demonstrated to be an effective and safe drug in treatment of the neuropathic pain in carrier patients of Post-herpetic Neuralgia and Painful Peripheral Diabetic Neuralgia.

Palabras llave : Pregabalina; Neuropathic Pain Treatment.